PureTech Health (PRTC) said Monday that a phase 2 clinical trial of its drug deupirfenidone as a treatment of patients with idiopathic pulmonary fibrosis reached its primary endpoint.

IPF is a rare, progressive, and often fatal lung disease with a median survival of two to five years.

In the 26-week trial, patients given 825 mg doses of the deupirfenidone three times a day saw lung function improve 50% greater than those treated with pirfenidone, the standard of care, the company said.

Both 825 mg and 550 mg doses of the drug were "generally well-tolerated" in the 257-patient trial, the company said.

PureTech said it will discuss the phase 2 results with regulatory authorities to map out a future path for approvals.